Loading stock data…
PRTA
$9.67-1.06 (-9.88%)
Market ClosedLast close May 11
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prothena Corporation plc in the Healthcare sector is trading at $9.67. The stock is currently 18% below its 52-week high of $11.80, remaining 2.3% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why PRTA maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.67
Potential Upside
5%
Whystock Fair Value$10.15
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$21.40+121.3%
Range$8.00 – $36.00
Fundamentals
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$577.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.33
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.03%
Volume
Today's trading volume
845,931
Recent News
Earnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Prothena Corporation plc ( NASDAQ:PRTA ) last week reported its latest quarterly results, which makes it a good time...
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
On April 29, 2026, a rare-disease deal reshapes biotech M&A expectations as investors weigh tender terms.
3 Growth Companies Insiders Are Eager To Hold
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In this environment of growth and stability, companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business's operations and future prospects.
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.